Cargando…
Biobetters From an Integrated Computational/Experimental Approach
Biobetters are new drugs designed from existing peptide or protein-based therapeutics by improving their properties such as affinity and selectivity for the target epitope, and stability against degradation. Computational methods can play a key role in such design problems—by predicting the changes...
Autores principales: | Kuyucak, Serdar, Kayser, Veysel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Research Network of Computational and Structural Biotechnology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279740/ https://www.ncbi.nlm.nih.gov/pubmed/28179976 http://dx.doi.org/10.1016/j.csbj.2017.01.003 |
Ejemplares similares
-
Future of anti-VEGF: biosimilars and biobetters
por: Kapur, Monika, et al.
Publicado: (2022) -
Biosimilar, biobetter and next generation therapeutic antibodies
Publicado: (2011) -
From Biologics to Biosimilars and Biobetters – Democratization of High-end Therapeutics
por: Honavar, Santosh G
Publicado: (2021) -
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters
por: Kim, HoUng, et al.
Publicado: (2021) -
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
por: Strohl, William R.
Publicado: (2015)